Candoxatril

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 585330

CAS#: 123122-55-4

Description: Candoxatril is a neutral endopeptidase inhibitor and natriuretic used in the treatment of hypertension.

Chemical Structure

img
Candoxatril
CAS# 123122-55-4
Instruction

Theoretical Analysis

MedKoo Cat#: 585330
Name: Candoxatril
CAS#: 123122-55-4
Chemical Formula: C29H41NO7
Exact Mass: 515.29
Molecular Weight: 515.647
Elemental Analysis: C, 67.55; H, 8.01; N, 2.72; O, 21.72

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Candoxatril; UK-79,300; UK79,300; UK 79,300

IUPAC/Chemical Name: 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid

InChi Key: ZTWZVMIYIIVABD-RZMWZJFBSA-N

InChi Code: InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21?,23-,24?/m0/s1

SMILES Code: O=C(C1CCC(NC(C2(C[C@@H](COCCOC)C(OC3=CC4=C(CCC4)C=C3)=O)CCCC2)=O)CC1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 515.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992 Jul;10(7):607-13. PubMed PMID: 1321186.

2: Newby DE, McDonagh T, Currie PF, Northridge DB, Boon NA, Dargie HJ. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Eur Heart J. 1998 Dec;19(12):1808-13. PubMed PMID: 9886723.

3: Motwani JG, Lang CC, Allen MJ, Johnson HF, Struthers AD. Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure. Clin Pharmacol Ther. 1993 Dec;54(6):661-9. PubMed PMID: 8275621.

4: Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014 Dec;2(6):663-70. doi: 10.1016/j.jchf.2014.09.001. Epub 2014 Oct 8. Review. PubMed PMID: 25306450.

5: Westheim AS, Bostrøm P, Christensen CC, Parikka H, Rykke EO, Toivonen L. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol. 1999 Nov 15;34(6):1794-801. PubMed PMID: 10577572.

6: Elsner D, Müntze A, Kromer EP, Riegger GA. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol. 1992 Aug 15;70(4):494-8. PubMed PMID: 1386491.

7: Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension. 1995 Dec;26(6 Pt 2):1160-6. PubMed PMID: 7498988.

8: Northridge DB, Newby DE, Rooney E, Norrie J, Dargie HJ. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J. 1999 Dec;138(6 Pt 1):1149-57. PubMed PMID: 10577447.

9: Northridge DB, Currie PF, Newby DE, McMurray JJ, Ford M, Boon NA, Dargie HJ. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail. 1999 Mar;1(1):67-72. PubMed PMID: 10937982.

10: O'Connell JE, Jardine AG, Davidson G, Connell JM. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992 Mar;10(3):271-7. PubMed PMID: 1315825.

11: Burk MJ, Bienewald F, Challenger S, Derrick A, Ramsden JA. Me-DuPHOS-Rh-Catalyzed Asymmetric Synthesis of the Pivotal Glutarate Intermediate for Candoxatril. J Org Chem. 1999 Apr 30;64(9):3290-3298. PubMed PMID: 11674433.

12: Kaye B, Brearley CJ, Cussans NJ, Herron M, Humphrey MJ, Mollatt AR. Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril. Xenobiotica. 1997 Oct;27(10):1091-102. PubMed PMID: 9364744.

13: McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997 Mar;43(3):329-32. PubMed PMID: 9088591; PubMed Central PMCID: PMC2042739.

14: Lang CC, Motwani J, Coutie WJ, Struthers AD. Influence of candoxatril on plasma brain natriuretic peptide in heart failure. Lancet. 1991 Jul 27;338(8761):255. Erratum in: Lancet 1991 Aug 10;338(8763):394. PubMed PMID: 1676808.

15: Yoshida K, Kanazawa M, Casley DJ, Katopothis A, Johnston CI. Inhibition of kidney neutral endopeptidase after administration of the neutral endopeptidase inhibitor candoxatril: quantitation by autoradiography. J Cardiovasc Pharmacol. 1998 Nov;32(5):702-8. PubMed PMID: 9821842.

16: McDowell G, Nicholls DP. The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert Opin Investig Drugs. 1999 Jan;8(1):79-84. PubMed PMID: 15992061.

17: Eizenberg Y, Grossman E, Peleg E, Shabtai Z, Sharabi Y. Neutral endopeptidase inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the metabolic syndrome. J Am Soc Hypertens. 2014 Apr;8(4):227-31. doi: 10.1016/j.jash.2014.01.006. Epub 2014 Jan 24. PubMed PMID: 24560177.

18: Davidson EP, Coppey LJ, Dake B, Yorek MA. Effect of Treatment of Sprague Dawley Rats with AVE7688, Enalapril, or Candoxatril on Diet-Induced Obesity. J Obes. 2011;2011. pii: 686952. doi: 10.1155/2011/686952. Epub 2010 Aug 16. PubMed PMID: 20847891; PubMed Central PMCID: PMC2933895.

19: Windeløv JA, Wewer Albrechtsen NJ, Kuhre RE, Jepsen SL, Hornburg D, Pedersen J, Jensen EP, Galsgaard KD, Winther-Sørensen M, Ørgaard A, Deacon CF, Mann M, Kissow H, Hartmann B, Holst JJ. Why is it so difficult to measure glucagon-like peptide-1 in a mouse? Diabetologia. 2017 Oct;60(10):2066-2075. doi: 10.1007/s00125-017-4347-7. Epub 2017 Jul 1. PubMed PMID: 28669086.

20: Angus RM, McCallum MJ, Nally JE, Thomson NC. No effect of the oral neutral endopeptidase inhibitor candoxatril, on bronchomotor tone and histamine reactivity in asthma. Eur Respir J. 1994 Jun;7(6):1084-9. PubMed PMID: 7925877.